Servier to Acquire Day One Biopharmaceuticals for $2.5 Billion – French Pharma Expands U.S. Oncology Presence with ADC Assets
Servier Group announced a definitive agreement to acquire Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) for...
Deals
Boan Biotech Partners with DP Technology on AI4S Drug Discovery – Antibody, ADC, and TCE Pipeline Acceleration
Shandong Boan Biotechnology Co., Ltd (HKG: 6955) announced a strategic cooperation agreement with DP Technology...
AstraGenomics and Kactus Forge Gene Editing Partnership – Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics
AstraGenomics and Kactus announced a strategic collaboration agreement to accelerate development and commercialization of nucleic...
Rallybio to Acquire Candid Therapeutics in $700M+ Merger – Creates Leading Autoimmune T‑Cell Engager Company
Rallybio Corporation (NASDAQ: RLYB) and Candid Therapeutics, Inc. announced a definitive merger agreement whereby Rallybio will...
Edding Genor Expands ANGPTL3 siRNA Rights to Global – Restructures Napeptide Partnership
Edding Genor Group Holdings Limited (HKG: 6998) announced a supplemental agreement and termination agreement with Napeptide...
Aidea Pharma Raises RMB 1.28B – $111M Allocated to Global HIV Integrase Inhibitor Development
Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) announced the completion of a financing round raising RMB 1.277 billion...
Star Sports Medicine Files Hong Kong IPO – Sports Medical Device Maker Targets Soft Tissue Injury Market
Star Sports Medicine Co., Ltd., a China‑based sports medical device manufacturer, submitted a prospectus to...
Leman Biotech Raises RMB 200M Series A+ – Advances Ultra‑Low‑Dose Metabolically Armored CAR‑T
Leman Biotech Co., Ltd. announced the completion of a Series A+ financing round totaling nearly...
Teva Secures $400M Blackstone Funding for Duvakitug – TL1A Antibody Advances in IBD Phase III
Teva Pharmaceuticals (NYSE: TEVA) and Blackstone Life Sciences (BXLS) announced a $400 million strategic funding agreement over...
Antengene Licenses ATG-201 to UCB in $1.1B+ Deal – CD19/CD3 T‑Cell Engager Targets Autoimmune Diseases
Antengene Corp., Ltd (HKG: 6996) announced a licensing agreement with UCB (EBR: UCB), granting the Belgium‑based biopharma...
Sino Biopharma Licenses Rovadicitinib to Sanofi in $1.53B Deal – First‑in‑Class JAK/ROCK Inhibitor Goes Global
Sino Biopharmaceutical Ltd (HKG: 1177) announced a licensing agreement with Sanofi SA (NASDAQ: SNY) for rovadicitinib, a...
Nanjing Novlead Bio Files Hong Kong IPO – Nitric Oxide Therapy Specialist Targets Critical Care Market
Nanjing Novlead Biotechnology Co., Ltd., a nitric oxide (NO) gas detection and treatment specialist, filed...
Boehringer Ingelheim Licenses Sitryx Autoimmune Program – $500M+ Deal for Oral Disease‑Modifying Therapy
Boehringer Ingelheim (BI) announced a licensing agreement with Sitryx Therapeutics, obtaining exclusive global rights to...
ArkBio Partners with Qilu Pharma on Azstarys China Commercialization – ADHD Therapy Market Entry
Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) announced a partnership with Qilu Pharmaceutical Co., Ltd. to...
QL Biopharma Raises 500M+ RMB Series C – OrbiMed Leads Round for Monthly GLP‑1 Zovigrutide
Beijing QL Biopharmaceutical Co., Ltd. announced the completion of a Series C financing round raising...
Tonghua Dongbao Partners with Huisheng Biopharma – Secures China Rights to First Domestic Insulin Degludec Biosimilars
Tonghua Dongbao Pharmaceuticals Co., Ltd (SHA: 600867) and Huisheng Biopharmaceutical Co., Ltd. announced a Commercialization Cooperation...
Jumpcan Pharma Secures China Rights to Thederma’s TAP-1503 – First AhR Modulator for Atopic Dermatitis
Jumpcan Pharmaceutical (SHA: 600566) announced a cooperation agreement with Shanghai‑based Thederma, securing exclusive commercialization rights in...
WuXi XDC Licenses WuXiTecan-2 Technology to Earendil Labs – $885M Deal Powers AI‑Driven ADC Development
WuXi XDC (HKG: 2268), a leading global end‑to‑end CRDMO, announced a strategic collaboration with Earendil Labs,...
SteinCares Partners with Shilpa Biologicals on Latin America Biosimilar Deal – Regional Commercialization Agreement
SteinCares, a leading specialty healthcare company in Latin America, and Shilpa Biologicals Pvt. Ltd. (SBPL),...
Danaher to Acquire Masimo for $9.9B – Expands Diagnostics Platform with Pulse Oximetry Leader
Danaher Corporation announced a definitive agreement to acquire Masimo Corporation (NASDAQ: MASI), a leading professional diagnostics...